Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Phase III study of VR-475 in severe uncontrolled asthma does not meet primary endpoint

Nov. 26, 2018

REALIST study explores use of mesenchymal stem cells to treat ARDS

Nov. 22, 2018

Phase I data on BLU-5937 support progression to phase II for chronic cough

Nov. 20, 2018

Phase III trial of STAGR-320 in house dust mite-induced allergic rhinitis meets primary endpoint

Nov. 20, 2018

Proteostasis Therapeutics patents mutant CFTR correctors

Nov. 19, 2018

Bridge Biotherapeutics files IND for BBT-877

Nov. 19, 2018

Redx nominates oral porcupine inhibitor RXC-006 as development compound to treat IPF

Nov. 15, 2018

FDA approves Oralair to treat grass pollen-induced allergic rhinitis in pediatric patients

Nov. 14, 2018

FDA approves Yupelri for maintenance treatment of COPD

Nov. 12, 2018

GlaxoSmithKline patents PI3K inhibitors

Nov. 12, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...